XLO XILIO THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, XILIO THERAPEUTICS INC reported revenue of $18.7M (up 131.2% from a year earlier), net income of −$6.37M and diluted EPS of −$0.33; over the last four quarters revenue was $64.1M and net income −$21.8M; for the fiscal year ended December 2025 revenue was $43.8M, up 589.9% on the year before.
XLO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $43.8M, gross profit n/a, operating income −$42.0M, net income −$35.0M (margin -80.1%), EPS −$4.19
- Fiscal year ended Dec 2024: revenue $6.34M, gross profit n/a, operating income −$60.6M, net income −$58.2M (margin -918.0%), EPS −$15.24
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$79.1M, net income −$76.4M (margin n/a), EPS −$2.78
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$89.1M, net income −$88.2M (margin n/a), EPS −$3.22
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$75.0M, net income −$75.8M (margin n/a), EPS −$13.52
XLO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $18.7M (up 131.2% year over year), net income −$6.37M, EPS −$0.33
- Quarter ended Mar 31, 2026: revenue $12.6M (up 331.7% year over year), net income −$9.53M, EPS −$0.58
- Quarter ended Dec 31, 2025 (from the annual report): revenue $13.7M, net income $10.4M, EPS $0.71
- Quarter ended Sep 30, 2025: revenue $19.1M (up 742.5% year over year), net income −$16.3M, EPS −$0.11
- Quarter ended Jun 30, 2025: revenue $8.08M (up 243.0% year over year), net income −$15.8M, EPS −$2.30
- Quarter ended Mar 31, 2025: revenue $2.93M, net income −$13.3M, EPS −$2.49
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$13.1M, EPS −$14.16
- Quarter ended Sep 30, 2024: revenue $2.26M, net income −$14.0M, EPS −$0.22
- Quarter ended Jun 30, 2024: revenue $2.36M, net income −$13.9M, EPS −$0.24
- Quarter ended Mar 31, 2024: revenue n/a, net income −$17.2M, EPS −$0.62
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$17.7M, EPS −$0.64
- Quarter ended Sep 30, 2023: revenue n/a, net income −$16.7M, EPS −$0.61
- Quarter ended Jun 30, 2023: revenue n/a, net income −$19.4M, EPS −$0.70
- Quarter ended Mar 31, 2023: revenue n/a, net income −$22.6M, EPS −$0.83
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$22.5M, EPS −$0.82
- Quarter ended Sep 30, 2022: revenue n/a, net income −$19.8M, EPS −$0.72
- Quarter ended Jun 30, 2022: revenue n/a, net income −$24.6M, EPS −$0.90
- Quarter ended Mar 31, 2022: revenue n/a, net income −$21.4M, EPS −$0.78
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$19.7M, EPS $62.76
- Quarter ended Sep 30, 2021: revenue n/a, net income −$16.3M, EPS −$21.27
XLO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$4.99M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$18.4M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$68.6M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$75.7M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$80.8M, share buybacks n/a
XLO balance sheet
- Jun 30, 2026: cash $136M, total assets $154M, total liabilities $82.0M, shareholders' equity $72.3M
- Mar 31, 2026: cash $150M, total assets $163M, total liabilities $90.9M, shareholders' equity $72.5M
- Dec 31, 2025: cash $138M, total assets $155M, total liabilities $119M, shareholders' equity $35.3M
- Sep 30, 2025: cash $104M, total assets $134M, total liabilities $142M, shareholders' equity −$8.10M
- Jun 30, 2025: cash $122M, total assets $134M, total liabilities $127M, shareholders' equity $7.07M
- Mar 31, 2025: cash $89.1M, total assets $104M, total liabilities $93.0M, shareholders' equity $10.7M
- Dec 31, 2024: cash $55.3M, total assets $71.1M, total liabilities $53.5M, shareholders' equity $17.6M
- Sep 30, 2024: cash $61.3M, total assets $74.7M, total liabilities $53.7M, shareholders' equity $21.0M
What is XLO's revenue?
XILIO THERAPEUTICS INC reported $64.1M of revenue over its last four quarters, through June 30, 2026.
Is XLO profitable?
No. XILIO THERAPEUTICS INC lost $21.8M over the last four quarters.
What is XLO's EPS?
Diluted earnings per share over the last four quarters were −$0.31; −$0.33 in the latest quarter.